Exoti Group, a global medical-device company, said Tuesday that its new products raised $200.5 million in sales in its second quarter, with more than $2.3 billion in revenue.
The firm reported a loss of $4.3 million for the quarter.
Exoti said it also made an adjusted net loss of approximately $1.2 billion, or $0.28 per share.
The company said it expects earnings per share of between $2 and $2,200 per share in the second quarter.
The $200 million revenue, or a 12% increase over the prior year, came from the launch of a new type of pregnancy monitor, Exoti’s pregnancy monitor that it says is better than previous ones.
It said it sold $3.7 million of the device in the quarter, bringing its total sales to more than 2.5 billion units.
The monitor also sold for $10,000, a record price for a pregnancy-monitor device.
Exotic drugs are used in medical devices, but they’re usually not covered by insurance.
The devices also do not come with a prescription, so patients can’t find them on their own.
Exact sales figures for Exoti are not available.
The results were expected.
Exotek, another global medical device maker, reported a net loss for the third quarter of $1 million.
The revenue came from sales of Exotak’s new, smaller-sized Exotic brand, which it says delivers superior results in women with less time to wait to conceive and less chance of having an ectopic pregnancy.
Exotics are used for pain management, but not to treat serious conditions like cancer or infertility.
The business also reported a $9.6 million loss, or 15 cents per share, in the year-ago period.
It reported revenue of $3 billion, up from $2 billion a year ago.
Analysts were not immediately available for comment.
Exotoix, another medical device company, reported sales of $5.3 a share, or 13 cents per stock.
Exota, a medical-equipment company, also reported sales for the first half of the year of $2 million, or 31 cents per shares.
The earnings came in on a year-over-year basis, rather than a percentage point increase.
Exotech, a healthcare technology company, lost $7.3, or 19 cents per unit.
It was a big hit.
The profit, though, came at a lower price.
The average price for Exotech products was $17.40, a 12-cent decrease from the previous quarter, and the company’s average revenue per unit was $922, down 12 cents from the same period last year.
Extech also reported the biggest loss ever in the medical device business.
The unit price of Exotech devices, which include birth control, sterilization and emergency contraception, dropped 19 cents to $12.90 per device, a price that’s the same as it was last year, and an increase from the prior quarter.
Analytically, Exotech was hurt by its high-cost contraceptive products, and by a drop in the number of people using them, the firm said.
Sales for Exotix, which includes birth control and sterilization, fell 12 cents to 6,766, a fall of 25% from a year earlier.
Exoce, a biotech company, posted a profit of $10.3 per share for the year, or 12 cents per diluted share.
Analytic analysts were not available for immediate comment.
SOURCE NBC News/CBS News, Health Care & Labor News, Media &, Medical Device, Exotic, Medical Devices, Healthcare